AAVB 081
Alternative Names: AAVB-081Latest Information Update: 20 Sep 2024
At a glance
- Originator AAVantgarde Bio
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Myosin VIIa replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Usher syndrome type 1B
Most Recent Events
- 02 Jul 2024 Phase-I/II clinical trials in Usher syndrome type 1B in Italy (Subretinal) (NCT06591793)
- 08 May 2024 AAVantgarde plans a first-in-human phase I/II LUCE-1 trial for Usher syndrome type 1B (Ophthalmic)
- 06 Jun 2023 Preclinical trials in Usher syndromes in Italy (Opthalmic) (AAVantgarde pipeline, June 2023)